Barriers to drug discovery and development for Alzheimer disease.
about
Economic analysis of opportunities to accelerate Alzheimer's disease research and development.Study design in dementia drug trials.Both Met(109) and Met(112) are utilized for Cu(II) coordination by the amyloidogenic fragment of the human prion protein at physiological pH.Neuroendocrinology-based therapy for Alzheimer's disease.Biomarker-driven therapeutic management of Alzheimer's disease: establishing the foundations.The molecular behavior of a single β-amyloid inside a dipalmitoylphosphatidylcholine bilayer at three different temperatures: An atomistic simulation study: Aβ interaction with DPPC: Atomistic simulation.
P2860
Barriers to drug discovery and development for Alzheimer disease.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Barriers to drug discovery and development for Alzheimer disease.
@ast
Barriers to drug discovery and development for Alzheimer disease.
@en
Barriers to drug discovery and development for Alzheimer disease.
@nl
type
label
Barriers to drug discovery and development for Alzheimer disease.
@ast
Barriers to drug discovery and development for Alzheimer disease.
@en
Barriers to drug discovery and development for Alzheimer disease.
@nl
prefLabel
Barriers to drug discovery and development for Alzheimer disease.
@ast
Barriers to drug discovery and development for Alzheimer disease.
@en
Barriers to drug discovery and development for Alzheimer disease.
@nl
P2093
P1476
Barriers to drug discovery and development for Alzheimer disease
@en
P2093
Alan W O'Connell
C Forbes Dewey
Howard M Fillit
June Kinoshita
Katherine Collins
Larry D Altstiel
Linda Van Eldik
Ravi Anand
William M Brown
P356
10.1097/00002093-200200001-00001
P407
P478
16 Suppl 1
P577
2002-01-01T00:00:00Z